Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Azin Nezami

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Journal of Medicinal Chemistry|March 29, 2014
Identification of novel HSP90α/β isoform selective inhibitors using structure-based drug design. demonstration of potential utility in treating CNS disorders such as Huntington's diseaseJustin T Ernst, Timothy Neubert, Michael Liu, et al.
Antimicrobial Agents and Chemotherapy|December 31, 2014
Preclinical activity of VX-787, a first-in-class, orally bioavailable inhibitor of the influenza virus polymerase PB2 subunitRandal A Byrn, Steven M Jones, Hamilton B Bennett, et al.
Journal of Medicinal Chemistry|July 15, 2014
Discovery of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of influenza PB2Michael P Clark, Mark W Ledeboer, Ioana Davies, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Journal of Medicinal Chemistry|March 29, 2014
Identification of novel HSP90α/β isoform selective inhibitors using structure-based drug design. demonstration of potential utility in treating CNS disorders such as Huntington's diseaseJustin T Ernst, Timothy Neubert, Michael Liu, et al.
Antimicrobial Agents and Chemotherapy|December 31, 2014
Preclinical activity of VX-787, a first-in-class, orally bioavailable inhibitor of the influenza virus polymerase PB2 subunitRandal A Byrn, Steven M Jones, Hamilton B Bennett, et al.
Journal of Medicinal Chemistry|July 15, 2014
Discovery of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of influenza PB2Michael P Clark, Mark W Ledeboer, Ioana Davies, et al.
Pageof 2